Literature DB >> 27892950

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

J C Albring1, S Inselmann2, T Sauer1, C Schliemann1, B Altvater3, S Kailayangiri3, C Rössig3, W Hartmann4, J R Knorrenschild2, K Sohlbach2, C Groth1, M Lohoff2, A Neubauer2, W E Berdel1, A Burchert2, M Stelljes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27892950     DOI： 10.1038/bmt.2016.274

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  J A Yared; N Hardy; Z Singh; S Hajj; A Z Badros; M Kocoglu; S Yanovich; E A Sausville; C Ujjani; K Ruehle; C Goecke; M Landau; A P Rapoport
Journal:  Bone Marrow Transplant       Date:  2016-02-01       Impact factor: 5.483

Review 2.  Immune checkpoint blockade in hematologic malignancies.

Authors:  Philippe Armand
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

3.  Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.

Authors:  Thomas S Y Chan; Pek-Lan Khong; Yok-Lam Kwong
Journal:  Ann Hematol       Date:  2016-07-30       Impact factor: 3.673

4.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 6.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 7.  Relapse after allogeneic stem cell transplantation.

Authors:  A John Barrett; Minoo Battiwalla
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

8.  Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.

Authors:  T Sauer; G Silling; C Groth; F Rosenow; U Krug; D Görlich; G Evers; J Albring; R Besoke; R M Mesters; C Müller-Tidow; T Kessler; T Büchner; W E Berdel; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

9.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

10.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

Authors:  Maximilian Christopeit; Oliver Kuss; Jürgen Finke; Ulrike Bacher; Dietrich Wilhelm Beelen; Martin Bornhäuser; Rainer Schwerdtfeger; Wolfgang Andreas Bethge; Nadezda Basara; Martin Gramatzki; Johanna Tischer; Hans-Jochem Kolb; Lutz Uharek; Ralf G Meyer; Donald Bunjes; Christof Scheid; Hans Martin; Dietger Niederwieser; Nicolaus Kröger; Hartmut Bertz; Hubert Schrezenmeier; Christoph Schmid
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544
View more
  32 in total

1.  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-18       Impact factor: 2.205

Review 2.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

Review 3.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

Review 4.  Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Authors:  Christine M McMahon; Alexander E Perl
Journal:  Leuk Lymphoma       Date:  2018-09-20

Review 5.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

Review 6.  Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors:  Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

7.  Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Authors:  Jochen Greiner; Susanne Hofmann; Michael Schmitt; Marlies Götz; Markus Wiesneth; Hubert Schrezenmeier; Donald Bunjes; Hartmut Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

8.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

9.  NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).

Authors:  Moniek A de Witte; Jürgen Kuball; Jeffrey S Miller
Journal:  Curr Stem Cell Rep       Date:  2017-10-16

Review 10.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.